Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GFR alpha-1

GFR alpha-1

Brief Information

Name:Glial cell line-derived neurotrophic factor receptors
Target Synonym:Glial Cell Line-Derived Neurotrophic Factor Receptors
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GF1-H5224 Human Human GFR alpha-1 Protein, His Tag
ACRO Quality

Part of Bioactivity data

 GFR alpha-1 ELISA

Immobilized Human GDNF Protein, premium grade (Cat. No. GDF-H5219) at 2 μg/mL (100 μL/well) can bind Human GFR alpha-1 Protein, His Tag (Cat. No. GF1-H5224) with a linear range of 0.5-2 ng/mL (Routinely tested).

Synonym Name



GDNF family receptor alpha-1 (GFRA1) is also known as RET ligand 1 (RETL1), TGF-beta-related neurotrophic factor receptor 1 (TRNR1), is a novel glycosylphosphatidylinositol (GPI)-linked cell surface receptor, and belongs to the glial cell line-derived neurotrophic factor (GDNF) receptor subfamily. The GDNF family ligands comprises GDNF, Neurturin (NTN), Artemin, and Persephin. GDNF and NTN are two structurally related, potent neurotrophic factors that play key roles in the control of neuron survival and differentiation. GFRA1 mediates the association with and activation of the RET tyrosine kinase receptor (RTK), and subsequently initiates the RET signaling pathway. GFR alpha-mediated signaling plays an important role in the survival, differentiation, and migration of central and peripheral neurons, and is essential for the development of kidneys and the enteric nervous system, as well as the inflammatory response in some carciniomas.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NGM-386 NGM-386 Phase 1 Clinical Ngm Biopharmaceuticals Inc Obesity Details
NGM-395 NGM-395 Phase 1 Clinical Ngm Biopharmaceuticals Inc Non-alcoholic Fatty Liver Disease; Obesity Details
KLS-2031 KLS-2031 Phase 2 Clinical Kolon Life Science. Inc Radiculopathy Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message